Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN AND DEXAMETHASONE versus MOXEZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN AND DEXAMETHASONE versus MOXEZA.
CIPROFLOXACIN AND DEXAMETHASONE vs MOXEZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication and transcription. Dexamethasone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2 and reducing prostaglandin and leukotriene synthesis.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination.
4 drops into affected ear(s) twice daily for 7 days. Otic suspension; shake well before use.
400 mg orally once daily with or without food.
None Documented
None Documented
Ciprofloxacin: 3.7-4.3 hours (prolonged in renal impairment). Dexamethasone: 3-4 hours.
Terminal half-life: 12 hours; allows once-daily dosing
Ciprofloxacin: 50-70% unchanged in urine via glomerular filtration and tubular secretion; 20-35% in feces via biliary and intestinal secretion. Dexamethasone: primarily metabolized, <10% unchanged in urine; biliary/fecal excretion of metabolites.
Renal: 70% unchanged; biliary/fecal: 20%; metabolized: 10%
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic